Literature DB >> 28974561

Crk Tyrosine Phosphorylation Regulates PDGF-BB-inducible Src Activation and Breast Tumorigenicity and Metastasis.

Sushil Kumar1, Bin Lu2, Viralkumar Davra1, Peter Hornbeck3, Kazuya Machida4, Raymond B Birge5.   

Abstract

The activity of Src family kinases (Src being the prototypical member) is tightly regulated by differential phosphorylation on Tyr416 (positive) and Tyr527 (negative), a duet that reciprocally regulates kinase activity. The latter negative regulation of Src on Tyr527 is mediated by C-terminal Src kinase (CSK) that phosphorylates Tyr527 and maintains Src in a clamped negative regulated state by promoting an intramolecular association. Here it is demonstrated that the SH2- and SH3-domain containing adaptor protein CrkII, by virtue of its phosphorylation on Tyr239, regulates the Csk/Src signaling axis to control Src activation. Once phosphorylated, the motif (PIpYARVIQ) forms a consensus sequence for the SH2 domain of CSK to form a pTyr239-CSK complex. Functionally, when expressed in Crk-/- MEFs or in Crk+/+ HS683 cells, Crk Y239F delayed PDGF-BB-inducible Src Tyr416 phosphorylation. Moreover, expression of Crk Y239F in HS683 cells delayed Src kinase activation and suppressed the cell-invasive and -transforming phenotypes. Finally, through loss-of-function and epistasis experiments using CRISPR-Cas9-engineered 4T1 murine breast cancer cells, Crk Tyr239 is implicated in breast cancer tumor growth and metastasis in orthotopic immunocompetent 4T1 mice model of breast adenocarcinoma. These findings delineate a novel role for Crk Tyr239 phosphorylation in the regulation of Src kinases, as well as a potential molecular explanation for a long-standing question as to how Crk regulates the activation of Src kinases.Implications: These findings provide new perspectives on the versatility of Crk in cancer by demonstrating how Crk mechanistically drives, through a tyrosine phosphorylation-dependent manner, tumor growth, and metastasis. Mol Cancer Res; 16(1); 173-83. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28974561     DOI: 10.1158/1541-7786.MCR-17-0242

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  11 in total

1.  Cyclophilin A Inhibitor Debio-025 Targets Crk, Reduces Metastasis, and Induces Tumor Immunogenicity in Breast Cancer.

Authors:  Viralkumar Davra; Sushil Kumar; Tamjeed Saleh; Ke Geng; Stanley Kimani; Dhriti Mehta; Canan Kasikara; Brendan Smith; Nicholas W Colangelo; Bryan Ciccarelli; Hong Li; Edouard I Azzam; Charalampos G Kalodimos; Raymond B Birge
Journal:  Mol Cancer Res       Date:  2020-04-22       Impact factor: 5.852

2.  Novel drug candidate for the treatment of several soft‑tissue sarcoma histologic subtypes: A computational method using survival‑associated gene signatures for drug repurposing.

Authors:  Xia Yang; Wen-Ting Huang; Hua-Yu Wu; Rong-Quan He; Jie Ma; An-Gui Liu; Gang Chen
Journal:  Oncol Rep       Date:  2019-02-26       Impact factor: 3.906

3.  CXCL17-derived CD11b+Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB.

Authors:  Ya-Ling Hsu; Meng-Chi Yen; Wei-An Chang; Pei-Hsun Tsai; Yi-Chung Pan; Ssu-Hui Liao; Po-Lin Kuo
Journal:  Breast Cancer Res       Date:  2019-02-12       Impact factor: 6.466

Review 4.  The "Janus Face" of Platelets in Cancer.

Authors:  Maria Valeria Catani; Isabella Savini; Valentina Tullio; Valeria Gasperi
Journal:  Int J Mol Sci       Date:  2020-01-25       Impact factor: 5.923

5.  ELTD1 Promotes Gastric Cancer Cell Proliferation, Invasion and Epithelial-Mesenchymal Transition Through MAPK/ERK Signaling by Regulating CSK.

Authors:  Bo Sun; Fang-Jing Zhong
Journal:  Int J Gen Med       Date:  2021-08-27

6.  The Tumor Suppressor SASH1 Interacts With the Signal Adaptor CRKL to Inhibit Epithelial-Mesenchymal Transition and Metastasis in Colorectal Cancer.

Authors:  Fabian Christoph Franke; Johannes Müller; Miguel Abal; Eduardo Domínguez Medina; Ulrich Nitsche; Henri Weidmann; Solenne Chardonnet; Ewa Ninio; Klaus-Peter Janssen
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2018-09-11

7.  LINC00888 promoted tumorigenicity of melanoma via miR-126/CRK signaling axis.

Authors:  Wei Lu; Xiaohua Tao; Yibin Fan; Yi Tang; Xin Xu; Shasha Fan; Youming Huang; Yong Yu; Dan Luo
Journal:  Onco Targets Ther       Date:  2018-07-31       Impact factor: 4.147

Review 8.  Crk and CrkL as Therapeutic Targets for Cancer Treatment.

Authors:  Taeju Park
Journal:  Cells       Date:  2021-03-27       Impact factor: 6.600

9.  MicroRNA-215-5p Inhibits the Proliferation and Migration of Wilm's Tumor Cells by Targeting CRK.

Authors:  Wang Li; Li Lingdi; Dang Xiqiang; Liu Jiheng; Tan Xin; Huang Qin; Li Haisha
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

10.  microRNA-132 inhibits the proliferation, migration, and invasion of ovarian cancer cells by regulating CT10 oncogenic gene homolog II-related signaling pathways.

Authors:  Haiyan Jiang; Min Dai; Yao Wu; Yansong Dong; Lei Qi; Qinghua Xi; Guiwen Liang
Journal:  Transl Cancer Res       Date:  2020-07       Impact factor: 1.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.